english.prescrire.org > Spotlight > 100 most recent > Olaparib (Lynparza°) as "maintenance" therapy for certain advanced ovarian cancers after first-line chemotherapy

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Olaparib (Lynparza°) as "maintenance" therapy for certain advanced ovarian cancers after first-line chemotherapy

 Marketing Authorisations   Olaparib is authorised as "maintenance" treatment (with or without bevacizumab) in women with certain ovarian cancers following first-line chemotherapy. In both authorised clinical situations, the initial authorisation was based on a single double-blind randomised clinical trial, with an interim analysis showing no reduction in mortality after a median follow-up of about 40 months. As of mid-2023, longer-term results are available from both of these trials.
Full article available for download by subscribers

EDITORS' OPINION
New data

The data underpinning a drug's marketing authorisation are sometimes preliminary, sparse or incomplete. In some cases, the only data available are results from a non-comparative trial, or interim results from a single comparative trial, whose "final" results are not expected until later...

Full text available for download by subscribers

©Prescrire 1 February 2024

Source: "Olaparib (Lynparza°) as "maintenance" therapy for certain advanced ovarian cancers after first-line chemotherapy" Prescrire Int 2024; 33 (256): 37-38. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter

Subscribe now

See also:

"Olaparib (Lynparza°)
as adjuvant treatment
for certain breast cancers
with a BRCA mutation"
Prescrire Int 2024;
33 (256): 35-36.
Subscribers only


Read more:

This month's contents

All the subjects in
Prescrire's spotlight